{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:56Z","timestamp":1740107456673,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00280-019-03818-1","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T09:10:20Z","timestamp":1553159420000},"page":"661-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab dosing in hematological malignancies: an old question, revisited"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-4095","authenticated-orcid":false,"given":"Peter N.","family":"Morcos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"10","key":"3818_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Foa R et al (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232\u20132273. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0612-x\n                    \n                  . Epub 2017 Oct 5","journal-title":"Adv Ther"},{"issue":"10","key":"3818_CR2","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s12325-017-0610-z","volume":"34","author":"A Davies","year":"2017","unstructured":"Davies A, Berge C, Boehnke A et al (2017) Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther 34(10):2210\u20132231","journal-title":"Adv Ther"},{"key":"3818_CR3","unstructured":"Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) \n                    https:\/\/www.fda.gov\/AdvisoryCommittees\/Calendar\/ucm547160.htm\n                    \n                  . Accessed 2 Jan 2019"},{"key":"3818_CR4","unstructured":"Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) Roche Briefing package. \n                    https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/ucm547155.htm\n                    \n                  . Accessed 20 Mar 2019"},{"key":"3818_CR5","unstructured":"Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) FDA Briefing package. \n                    https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/ucm547155.htm\n                    \n                  . Accessed 20 Mar 2019"},{"key":"3818_CR6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M et al (2012) Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 52:1918\u20131926","journal-title":"J Clin Pharmacol"},{"key":"3818_CR7","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1038\/psp.2014.42","volume":"29;3","author":"E Gibiansky","year":"2014","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ et al (2014) Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin\u2019s lymphoma and exposure-response in CLL. CPT Pharmacomet Syst Pharmacol 29;3:e144. \n                    https:\/\/doi.org\/10.1038\/psp.2014.42","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"9","key":"3818_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA et al (1998) Association of serum rituximab (IDECC2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 9(9):995\u20131001","journal-title":"Ann Oncol"},{"key":"3818_CR9","unstructured":"Gibiansky E, Brewster M, Chavanne C et al (2015) Comparison of population PK and exposure-response relationships of intravenous rituximab and subcutaneous rituximab in patients with CLL. Poster session presented at: 2015 PAGE annual meeting, June 2\u20135, Hersonissos, Crete, Greece"},{"issue":"16","key":"3818_CR10","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","volume":"113","author":"D Dayde","year":"2009","unstructured":"Dayde D, Ternant D, Ohresser M et al (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113(16):3765\u20133772. \n                    https:\/\/doi.org\/10.1182\/blood-2008-08-175125\n                    \n                  \n                           (Epub 2008 Nov 24)","journal-title":"Blood"},{"issue":"suppl 15","key":"3818_CR11","doi-asserted-by":"publisher","first-page":"e13108","DOI":"10.1200\/jco.2010.28.15_suppl.e13108","volume":"28","author":"A Yin","year":"2010","unstructured":"Yin A, Li J, Hurst D et al (2010) Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 28(suppl 15):e13108","journal-title":"J Clin Oncol"},{"key":"3818_CR12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"3818_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000086769","volume":"68","author":"M Lazzarino","year":"2005","unstructured":"Lazzarino M, Arcaini L, Orlandi E et al (2005) Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. Oncology 68:146\u2013153","journal-title":"Oncology"},{"key":"3818_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"LN Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A et al (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096\u20131102","journal-title":"J Clin Oncol"},{"key":"3818_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdf155","volume":"13","author":"T Igarashi","year":"2002","unstructured":"Igarashi T, Kobayashi Y, Ogura M et al (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 13:928\u2013943","journal-title":"Ann Oncol"},{"key":"3818_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821\u2013830","journal-title":"Ann Oncol"},{"key":"3818_CR17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","volume":"97","author":"U J\u00e4ger","year":"2012","unstructured":"J\u00e4ger U, Fridrick M, Zeitlinger M et al (2012) Rituximab serum concentrations during immunochemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97:1431\u20131438","journal-title":"Haematologica"},{"key":"3818_CR18","unstructured":"Kamisoglu K, Phipps A, Jamois C et al (2017) Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi-mechanistic pharmacokinetic\/pharmacodynamic model. Blood 130(Suppl 1):1267. \n                    http:\/\/www.bloodjournal.org\/content\/130\/Suppl_1\/1267\n                    \n                  . Accessed 2 Jan 2019"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03818-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03818-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03818-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:12:28Z","timestamp":1584663148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03818-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3818"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03818-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"P. N. Morcos and A. Boehnke are employees of, and own stock\/stock options in, Roche. N Valente is an employee of Genentech and own stock\/stock options in Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in clinical studies with human subjects were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards and with the ethical standards of the institutional and\/or national research committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all human subjects included in the studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}